GWS
NTLA icon

Glassman Wealth Services’s Intellia Therapeutics NTLA Stock Holding History

Glassman Wealth Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-138
Closed -$4.21K – 1256
2023
Q4 		$4.21K Sell
138
-14
-9% -$402 ﹤0.01% 1128
2023
Q3 		$4.81K Buy
152
+46
+43% +$1.78K ﹤0.01% 1081
2023
Q2 		$4.32K Sell
106
-9
-8% -$365 ﹤0.01% 1040
2023
Q1 		$4.29K Sell
115
-61
-35% -$2.39K ﹤0.01% 1044
2022
Q4 		$6.14K Sell
176
-51
-22% -$2.42K ﹤0.01% 968
2022
Q3 		$13K Sell
227
-13
-5% -$806 ﹤0.01% 728
2022
Q2 		$12K Sell
240
-11
-4% -$559 ﹤0.01% 757
2022
Q1 		$18K Buy
251
+70
+39% +$5.93K ﹤0.01% 679
2021
Q4 		$21K Sell
181
-79
-30% -$9.9K ﹤0.01% 599
2021
Q3 		$35K Buy
260
+84
+48% +$12.7K 0.01% 436
2021
Q2 		$28K Buy
176
+4
+2% +$311 0.01% 476
2021
Q1 		$14K Buy
172
+2
+1% +$134 ﹤0.01% 635
2020
Q4 		$9K Buy
+170
New +$6.17K ﹤0.01% 748

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Glassman Wealth Services's NTLA Position: Q1 2024 in Review

Glassman Wealth Services sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 138 shares — an estimated $4.21K sold.

Glassman Wealth Services first reported a position in NTLA in Q4 2020 and held it in 13 quarters. The position peaked at $35K in Q3 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Glassman Wealth Services reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 138 Intellia Therapeutics shares in Q1 2024, an estimated $4.21K.
  • Glassman Wealth Services first reported a position in Intellia Therapeutics in Q4 2020 and held it in 13 quarters.
  • Glassman Wealth Services's Intellia Therapeutics position peaked at $35K in Q3 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.